Estrategia en EPOC del Sistema Nacional de Salud

59 Naberan K, de la Roza C, Lamban M, Gobartt E, Martín A, Miravitlles M. Use of spirometry in
the diagnosis and treatment of chronic obstructive pulmonary disease in Primary Care. Arch
Bronconeumol. 2006; 42: 638-644.
60 Miravitlles M, Fernández I, Guerrero T, Murio C. The development and efficacy of a primary
care screening program for chronic obstructive pulmonary disease. The PADOC project. Arch
Bronconeumol. 2000; 36: 500-505.
61 Clotet J, Gómez-Arbonés X, Ciria C, Albalad JM. Spirometry is a good method for detecting
and monitoring chronic obstructive pulmonary disease in high-risk smokers in primary health
care. Arch Bronconeumol. 2004; 40: 155–159.
62 Zieliñski J, Bednarek M, et al. Early detection of COPD in high-risk population using
spirometric screening. Chest. 2001;119:731-736.
63 Górecka D, Bednarek M, Nowinski A, Puscinska E, Golian-Geremek A, Zielinski J. Diagnosis
of airflow limitation combined with smoking cessation advice increases stop-smoking rate.
Chest. 2003; 123: 1916-1923.
64 American Thoracic Society (ATS). Lung function testing: selection of reference values and
interpretative strategies. Am Rev Respir Dis. 1991; 144: 1202-1218.
65
Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al.
Inspiratory to total lung capacity ratio predicts mortality in patients whit chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 2005; 171:591-7.
66 Soler-Cataluña JJ, Calle M, Cosio B, Marín JM, Monsó E. Estándares de calidad asistencial
en la EPOC. Arch Bronconeumol. 2009; 45(4): 196-203.
67 Escarrabill J, Soler-Cataluña JJ, Hernández C, Servera E. Recomendaciones sobre la
atención al final de vida en pacientes con EPOC. Arch Bronconeumol 2009 (en prensa).
68 Hernandez C, Casas A, Escarrabill J, et al. Home hospitalisation of exacerbated chronic
obstructive pulmonary disease patients. Eur Respir J. 2003; 21(1): 58-67.
69 Luppi F, Franco F, Beghé B, Fabbri LM. Treatment of chronic obstructive pulmonary disease
and its comorbidities. Proc Am Thorac Soc. 2008; 5: 848-56.
70 Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa JF, Verea H, Murio C, Ros
F, Vidal R, for the IMPAC study group. Exacerbations impair quality of life in patients with
chronic obstructive pulmonary disease. A two-year follow-up study. Thorax. 2004; 59: 387-395.
71 Soler-Cataluña JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando
R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary
disease. Thorax. 2005; 60: 925-31.
72 Soler Cataluña JJ. El papel de las exacerbaciones en la historia natural de la EPOC. Arch
Bronconeumol. 2007; 43(2): 55-8.
73 Soler JJ, Sánchez L, Latorre M, Alamar J, Román P, Perpiña M. Impacto asistencial
hospitalario de la EPOC. Peso específico del paciente con EPOC de alto consumo sanitario.
Arch Bronconeumol. 2001; 37: 375-381.
74 Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of
exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med. 1998; 157: 1418-22.
75 Doll H, Miravitlles M. Quality of life in acute exacerbations of chronic bronchitis and chronic
obstructive pulmonary disease: A review of the literature. Pharmacoeconomics 2005; 23: 345­
363.
76
Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between
exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
Thorax. 2002; 57: 847-852.
77 Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in
current smokers but not exsmokers with mild chronic obstructive pulmonary disease. Am J
Respir Crit Care Med. 2001; 164: 358-364.
194